Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Room MDCL-5071, 1200 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada.
Expert Rev Vaccines. 2011 Sep;10(9):1307-19. doi: 10.1586/erv.11.88.
Recombinant adenoviruses have emerged as promising viral vectors for CD8(+) T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8(+) T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-level transgene expression from the rHuAd5 vector sustains the CD8(+) T-cell memory population and a nonhematopoietic cell compartment appears to be involved in long-term presentation of adenoviral antigens. Although we are beginning to learn more about the factors that control the maintenance and functionality of memory CD8(+) T cells, we do not yet fully understand what comprises a protective CD8(+) T-cell response. Results from upcoming Phase II clinical trials will be important for determining whether rHuAd5 T-cell vaccines are effective in humans and should help identify correlates of CD8(+) T-cell protection.
重组腺病毒已成为有前途的 CD8(+)T 细胞疫苗的病毒载体。我们的研究表明，与大多数急性感染不同，由重组人腺病毒血清型 5（rHuAd5）引起的 CD8(+)T 细胞记忆群体表现出优势效应记忆表型。rHuAd5 载体持续的低水平转基因表达维持了 CD8(+)T 细胞记忆群体，非造血细胞似乎参与了腺病毒抗原的长期呈递。尽管我们开始更多地了解控制记忆 CD8(+)T 细胞的维持和功能的因素，但我们还不完全了解什么构成了保护性 CD8(+)T 细胞反应。即将进行的 II 期临床试验的结果对于确定 rHuAd5 T 细胞疫苗在人类中的有效性非常重要，并且应该有助于确定 CD8(+)T 细胞保护的相关因素。
